Sinovac Biotech Ltd - Asset Resilience Ratio
Sinovac Biotech Ltd (SVA) has an Asset Resilience Ratio of 63.90% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sinovac Biotech Ltd (SVA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Sinovac Biotech Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Sinovac Biotech Ltd.
Liquid Assets Composition Over Time
This chart breaks down Sinovac Biotech Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Sinovac Biotech Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.20 Billion | 63.9% |
| Total Liquid Assets | $5.20 Billion | 63.90% |
Asset Resilience Insights
- Very High Liquidity: Sinovac Biotech Ltd maintains exceptional liquid asset reserves at 63.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sinovac Biotech Ltd Industry Peers by Asset Resilience Ratio
Compare Sinovac Biotech Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Sinovac Biotech Ltd (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Sinovac Biotech Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.49% | $5.48 Billion | $8.64 Billion | -14.43pp |
| 2024-12-31 | 77.92% | $9.61 Billion | $12.34 Billion | +5.05pp |
| 2023-12-31 | 72.87% | $9.95 Billion | $13.66 Billion | +23.03pp |
| 2022-12-31 | 49.84% | $7.03 Billion | $14.11 Billion | +39.05pp |
| 2021-12-31 | 10.79% | $1.81 Billion | $16.75 Billion | +3.67pp |
| 2020-12-31 | 7.11% | $135.25 Million | $1.90 Billion | -4.00pp |
| 2019-12-31 | 11.12% | $50.27 Million | $452.30 Million | +6.00pp |
| 2018-12-31 | 5.11% | $18.91 Million | $369.78 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $211.35 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $211.35 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $202.93 Million | -- |
| 2014-12-31 | 0.63% | $1.50 Million | $238.53 Million | -0.08pp |
| 2010-12-31 | 0.71% | $1.51 Million | $214.36 Million | -4.32pp |
| 2009-12-31 | 5.03% | $7.31 Million | $145.48 Million | +5.03pp |
| 2007-12-31 | 0.00% | $1.00K | $57.45 Million | -0.06pp |
| 2006-12-31 | 0.06% | $24.00K | $37.01 Million | -0.57pp |
| 2005-12-31 | 0.64% | $149.00K | $23.37 Million | -1.11pp |
| 2004-12-31 | 1.74% | $391.00K | $22.42 Million | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more